Trevi Therapeutics (TRVI) said late Tuesday topline data from a human abuse potential study shows that its oral nalbuphine drug candidate, aimed at the treatment of chronic cough, had statistically significant lower "drug liking" compared with butorphanol.
Drug liking is a measure of the pleasurable experience after consuming a drug, often used to study their misuse liability.
The company added, however, that the supratherapeutic dose of oral nalbuphine at 486 milligrams "was numerically lower" than the 6mg IV butorphanol for drug liking "but the results were not statistically significant."
The study did not observe any serious adverse events, the company said.
Shares of Trevi Therapeutics were down more than 13% in after-hours activity Tuesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。